AU712015B2 - Triterpene derivatives with immunosuppressant activity - Google Patents

Info

Publication number

AU712015B2

AU712015B2 AU74781/96A AU7478196A AU712015B2 AU 712015 B2 AU712015 B2 AU 712015B2 AU 74781/96 A AU74781/96 A AU 74781/96A AU 7478196 A AU7478196 A AU 7478196A AU 712015 B2 AU712015 B2 AU 712015B2

Authority

AU

Australia

Prior art keywords

alkyl

defined above

aryl

heteroaryl

hydroxy

Prior art date

1995-10-31

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 150000003648 triterpenes Chemical class 0.000 title claims description 6
• 230000001861 immunosuppressant effect Effects 0.000 title description 4
• 150000001875 compounds Chemical class 0.000 claims description 130
• 125000003118 aryl group Chemical group 0.000 claims description 99
• 125000001072 heteroaryl group Chemical group 0.000 claims description 98
• 125000001424 substituent group Chemical group 0.000 claims description 91
• -1 nitro, hydroxy Chemical group 0.000 claims description 83
• 125000000217 alkyl group Chemical group 0.000 claims description 75
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 59
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 52
• 229910052731 fluorine Inorganic materials 0.000 claims description 52
• 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 51
• 201000004624 Dermatitis Diseases 0.000 claims description 50
• 229910052801 chlorine Inorganic materials 0.000 claims description 50
• 229910052794 bromium Inorganic materials 0.000 claims description 49
• 201000010099 disease Diseases 0.000 claims description 49
• 229910052740 iodine Inorganic materials 0.000 claims description 46
• 208000006673 asthma Diseases 0.000 claims description 45
• 238000000034 method Methods 0.000 claims description 45
• 239000000203 mixture Substances 0.000 claims description 33
• 229910052757 nitrogen Inorganic materials 0.000 claims description 32
• 125000003342 alkenyl group Chemical group 0.000 claims description 30
• 125000004432 carbon atom Chemical group C* 0.000 claims description 30
• 239000003814 drug Substances 0.000 claims description 28
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
• 238000011282 treatment Methods 0.000 claims description 28
• 125000004043 oxo group Chemical group O=* 0.000 claims description 27
• 229910052739 hydrogen Inorganic materials 0.000 claims description 26
• 210000000056 organ Anatomy 0.000 claims description 26
• 238000002054 transplantation Methods 0.000 claims description 26
• 229910052760 oxygen Inorganic materials 0.000 claims description 24
• 125000000304 alkynyl group Chemical group 0.000 claims description 22
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 22
• 150000003839 salts Chemical group 0.000 claims description 21
• 206010019663 Hepatic failure Diseases 0.000 claims description 20
• 229940079593 drug Drugs 0.000 claims description 20
• 208000007903 liver failure Diseases 0.000 claims description 20
• 231100000835 liver failure Toxicity 0.000 claims description 20
• 230000000694 effects Effects 0.000 claims description 19
• 208000009137 Behcet syndrome Diseases 0.000 claims description 16
• 208000010668 atopic eczema Diseases 0.000 claims description 16
• 230000001684 chronic effect Effects 0.000 claims description 16
• 206010046851 Uveitis Diseases 0.000 claims description 15
• 230000000302 ischemic effect Effects 0.000 claims description 15
• 125000001624 naphthyl group Chemical group 0.000 claims description 15
• 229910052717 sulfur Inorganic materials 0.000 claims description 15
• 206010019799 Hepatitis viral Diseases 0.000 claims description 14
• NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 claims description 14
• 206010023332 keratitis Diseases 0.000 claims description 14
• 206010011831 Cytomegalovirus infection Diseases 0.000 claims description 13
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 13
• 239000013078 crystal Chemical group 0.000 claims description 13
• 125000005842 heteroatom Chemical group 0.000 claims description 13
• 239000003018 immunosuppressive agent Substances 0.000 claims description 13
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 13
• 201000000306 sarcoidosis Diseases 0.000 claims description 13
• 210000001519 tissue Anatomy 0.000 claims description 13
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 12
• 108010036949 Cyclosporine Proteins 0.000 claims description 12
• 206010029240 Neuritis Diseases 0.000 claims description 12
• 208000007536 Thrombosis Diseases 0.000 claims description 12
• 210000004185 liver Anatomy 0.000 claims description 12
• 201000005962 mycosis fungoides Diseases 0.000 claims description 12
• 201000004384 Alopecia Diseases 0.000 claims description 11
• 206010015150 Erythema Diseases 0.000 claims description 11
• 231100000321 erythema Toxicity 0.000 claims description 11
• 238000009472 formulation Methods 0.000 claims description 11
• 239000001301 oxygen Substances 0.000 claims description 11
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 11
• 208000023275 Autoimmune disease Diseases 0.000 claims description 10
• 229930105110 Cyclosporin A Natural products 0.000 claims description 10
• 229960001265 ciclosporin Drugs 0.000 claims description 10
• 208000014674 injury Diseases 0.000 claims description 10
• 210000004072 lung Anatomy 0.000 claims description 10
• 230000001404 mediated effect Effects 0.000 claims description 10
• 229920002554 vinyl polymer Polymers 0.000 claims description 10
• 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 9
• 208000007788 Acute Liver Failure Diseases 0.000 claims description 9
• 206010000804 Acute hepatic failure Diseases 0.000 claims description 9
• 208000032467 Aplastic anaemia Diseases 0.000 claims description 9
• 206010016654 Fibrosis Diseases 0.000 claims description 9
• 201000004681 Psoriasis Diseases 0.000 claims description 9
• 230000007882 cirrhosis Effects 0.000 claims description 9
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 9
• 230000035939 shock Effects 0.000 claims description 9
• 208000017520 skin disease Diseases 0.000 claims description 9
• 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims description 8
• 241000124008 Mammalia Species 0.000 claims description 8
• 206010034277 Pemphigoid Diseases 0.000 claims description 8
• 208000000594 bullous pemphigoid Diseases 0.000 claims description 8
• 206010012601 diabetes mellitus Diseases 0.000 claims description 8
• 208000035475 disorder Diseases 0.000 claims description 8
• 208000006454 hepatitis Diseases 0.000 claims description 8
• 231100000283 hepatitis Toxicity 0.000 claims description 8
• 229940125721 immunosuppressive agent Drugs 0.000 claims description 8
• 230000005764 inhibitory process Effects 0.000 claims description 8
• 201000006417 multiple sclerosis Diseases 0.000 claims description 8
• 230000036961 partial effect Effects 0.000 claims description 8
• 208000023504 respiratory system disease Diseases 0.000 claims description 8
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
• 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 8
• 239000003053 toxin Substances 0.000 claims description 8
• 231100000765 toxin Toxicity 0.000 claims description 8
• 208000030507 AIDS Diseases 0.000 claims description 7
• 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
• 208000024827 Alzheimer disease Diseases 0.000 claims description 7
• 208000028185 Angioedema Diseases 0.000 claims description 7
• 206010002660 Anoxia Diseases 0.000 claims description 7
• 241000976983 Anoxia Species 0.000 claims description 7
• 208000033222 Biliary cirrhosis primary Diseases 0.000 claims description 7
• 201000009030 Carcinoma Diseases 0.000 claims description 7
• 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 7
• 208000002691 Choroiditis Diseases 0.000 claims description 7
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
• 208000011231 Crohn disease Diseases 0.000 claims description 7
• 206010012442 Dermatitis contact Diseases 0.000 claims description 7
• 206010014950 Eosinophilia Diseases 0.000 claims description 7
• 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 7
• 208000009329 Graft vs Host Disease Diseases 0.000 claims description 7
• 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 7
• 206010021143 Hypoxia Diseases 0.000 claims description 7
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
• GWNVDXQDILPJIG-SHSCPDMUSA-N Leukotriene C4 Natural products CCCCCC=C/CC=C/C=C/C=C/C(SCC(NC(=O)CCC(N)C(=O)O)C(=O)NCC(=O)O)C(O)CCCC(=O)O GWNVDXQDILPJIG-SHSCPDMUSA-N 0.000 claims description 7
• 208000012309 Linear IgA disease Diseases 0.000 claims description 7
• 241000701076 Macacine alphaherpesvirus 1 Species 0.000 claims description 7
• 206010027476 Metastases Diseases 0.000 claims description 7
• 206010028980 Neoplasm Diseases 0.000 claims description 7
• 206010033645 Pancreatitis Diseases 0.000 claims description 7
• 241000721454 Pemphigus Species 0.000 claims description 7
• 208000003971 Posterior uveitis Diseases 0.000 claims description 7
• 208000012654 Primary biliary cholangitis Diseases 0.000 claims description 7
• 206010038910 Retinitis Diseases 0.000 claims description 7
• 206010039966 Senile dementia Diseases 0.000 claims description 7
• 206010040047 Sepsis Diseases 0.000 claims description 7
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 7
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 7
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
• 208000024780 Urticaria Diseases 0.000 claims description 7
• 206010047112 Vasculitides Diseases 0.000 claims description 7
• 206010047115 Vasculitis Diseases 0.000 claims description 7
• 206010000496 acne Diseases 0.000 claims description 7
• 230000001154 acute effect Effects 0.000 claims description 7
• 206010064930 age-related macular degeneration Diseases 0.000 claims description 7
• 230000032683 aging Effects 0.000 claims description 7
• 239000003513 alkali Substances 0.000 claims description 7
• 208000004631 alopecia areata Diseases 0.000 claims description 7
• 230000007953 anoxia Effects 0.000 claims description 7
• 230000003110 anti-inflammatory effect Effects 0.000 claims description 7
• 230000001363 autoimmune Effects 0.000 claims description 7
• 201000011510 cancer Diseases 0.000 claims description 7
• 239000004568 cement Substances 0.000 claims description 7
• 230000000973 chemotherapeutic effect Effects 0.000 claims description 7
• 208000010247 contact dermatitis Diseases 0.000 claims description 7
• 238000003912 environmental pollution Methods 0.000 claims description 7
• 208000007565 gingivitis Diseases 0.000 claims description 7
• 206010019692 hepatic necrosis Diseases 0.000 claims description 7
• 229960001340 histamine Drugs 0.000 claims description 7
• 230000003463 hyperproliferative effect Effects 0.000 claims description 7
• 206010021198 ichthyosis Diseases 0.000 claims description 7
• 230000002757 inflammatory effect Effects 0.000 claims description 7
• 201000010666 keratoconjunctivitis Diseases 0.000 claims description 7
• GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 claims description 7
• 201000011486 lichen planus Diseases 0.000 claims description 7
• 231100000149 liver necrosis Toxicity 0.000 claims description 7
• 206010025135 lupus erythematosus Diseases 0.000 claims description 7
• 230000009401 metastasis Effects 0.000 claims description 7
• 244000000010 microbial pathogen Species 0.000 claims description 7
• 206010028417 myasthenia gravis Diseases 0.000 claims description 7
• 230000017074 necrotic cell death Effects 0.000 claims description 7
• 201000001245 periodontitis Diseases 0.000 claims description 7
• 238000002271 resection Methods 0.000 claims description 7
• 230000037390 scarring Effects 0.000 claims description 7
• 208000010157 sclerosing cholangitis Diseases 0.000 claims description 7
• 208000004003 siderosis Diseases 0.000 claims description 7
• 230000008733 trauma Effects 0.000 claims description 7
• 201000001862 viral hepatitis Diseases 0.000 claims description 7
• 208000009304 Acute Kidney Injury Diseases 0.000 claims description 6
• 208000026872 Addison Disease Diseases 0.000 claims description 6
• 201000010000 Agranulocytosis Diseases 0.000 claims description 6
• 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 6
• 206010002065 Anaemia megaloblastic Diseases 0.000 claims description 6
• 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
• 201000001320 Atherosclerosis Diseases 0.000 claims description 6
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 claims description 6
• 206010003827 Autoimmune hepatitis Diseases 0.000 claims description 6
• 208000035143 Bacterial infection Diseases 0.000 claims description 6
• 208000023328 Basedow disease Diseases 0.000 claims description 6
• 108010006654 Bleomycin Proteins 0.000 claims description 6
• 208000031229 Cardiomyopathies Diseases 0.000 claims description 6
• 206010009657 Clostridium difficile colitis Diseases 0.000 claims description 6
• 208000015943 Coeliac disease Diseases 0.000 claims description 6
• 208000035473 Communicable disease Diseases 0.000 claims description 6
• 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 6
• 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 6
• 206010014561 Emphysema Diseases 0.000 claims description 6
• 206010016228 Fasciitis Diseases 0.000 claims description 6
• 208000024869 Goodpasture syndrome Diseases 0.000 claims description 6
• 206010018691 Granuloma Diseases 0.000 claims description 6
• 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 6
• 208000032759 Hemolytic-Uremic Syndrome Diseases 0.000 claims description 6
• 208000005100 Herpetic Keratitis Diseases 0.000 claims description 6
• 206010020850 Hyperthyroidism Diseases 0.000 claims description 6
• 206010021074 Hypoplastic anaemia Diseases 0.000 claims description 6
• 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims description 6
• 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 6
• 201000002287 Keratoconus Diseases 0.000 claims description 6
• 206010024380 Leukoderma Diseases 0.000 claims description 6
• 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
• 208000000682 Megaloblastic Anemia Diseases 0.000 claims description 6
• 208000027530 Meniere disease Diseases 0.000 claims description 6
• 208000019695 Migraine disease Diseases 0.000 claims description 6
• 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 6
• 206010027910 Mononeuritis Diseases 0.000 claims description 6
• 208000024599 Mooren ulcer Diseases 0.000 claims description 6
• 206010051606 Necrotising colitis Diseases 0.000 claims description 6
• 208000008589 Obesity Diseases 0.000 claims description 6
• 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims description 6
• 208000001132 Osteoporosis Diseases 0.000 claims description 6
• 208000031845 Pernicious anaemia Diseases 0.000 claims description 6
• 206010036105 Polyneuropathy Diseases 0.000 claims description 6
• 102100034355 Potassium voltage-gated channel subfamily A member 3 Human genes 0.000 claims description 6
• 206010036774 Proctitis Diseases 0.000 claims description 6
• 208000003100 Pseudomembranous Enterocolitis Diseases 0.000 claims description 6
• 206010037128 Pseudomembranous colitis Diseases 0.000 claims description 6
• 208000003670 Pure Red-Cell Aplasia Diseases 0.000 claims description 6
• 208000006311 Pyoderma Diseases 0.000 claims description 6
• 206010037779 Radiculopathy Diseases 0.000 claims description 6
• 208000033626 Renal failure acute Diseases 0.000 claims description 6
• 208000002200 Respiratory Hypersensitivity Diseases 0.000 claims description 6
• 206010039710 Scleroderma Diseases 0.000 claims description 6
• 206010040070 Septic Shock Diseases 0.000 claims description 6
• 208000021386 Sjogren Syndrome Diseases 0.000 claims description 6
• 208000007107 Stomach Ulcer Diseases 0.000 claims description 6
• 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 6
• 208000001106 Takayasu Arteritis Diseases 0.000 claims description 6
• 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 6
• 231100000579 Toxinosis Toxicity 0.000 claims description 6
• 206010064996 Ulcerative keratitis Diseases 0.000 claims description 6
• 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 claims description 6
• 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 claims description 6
• 230000010085 airway hyperresponsiveness Effects 0.000 claims description 6
• 201000009961 allergic asthma Diseases 0.000 claims description 6
• 208000002205 allergic conjunctivitis Diseases 0.000 claims description 6
• 231100000360 alopecia Toxicity 0.000 claims description 6
• 208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
• 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 6
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
• OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical class N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 6
• 210000000988 bone and bone Anatomy 0.000 claims description 6
• 206010006451 bronchitis Diseases 0.000 claims description 6
• 230000000747 cardiac effect Effects 0.000 claims description 6
• 208000015114 central nervous system disease Diseases 0.000 claims description 6
• 208000020832 chronic kidney disease Diseases 0.000 claims description 6
• 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 6
• 201000010002 cicatricial pemphigoid Diseases 0.000 claims description 6
• 206010009887 colitis Diseases 0.000 claims description 6
• 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 6
• 201000001981 dermatomyositis Diseases 0.000 claims description 6
• 208000033679 diabetic kidney disease Diseases 0.000 claims description 6
• 239000003937 drug carrier Substances 0.000 claims description 6
• 239000000428 dust Substances 0.000 claims description 6
• 230000002327 eosinophilic effect Effects 0.000 claims description 6
• 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims description 6
• 208000024711 extrinsic asthma Diseases 0.000 claims description 6
• 230000035784 germination Effects 0.000 claims description 6
• 210000004195 gingiva Anatomy 0.000 claims description 6
• 230000003779 hair growth Effects 0.000 claims description 6
• 201000010884 herpes simplex virus keratitis Diseases 0.000 claims description 6
• 201000002597 ichthyosis vulgaris Diseases 0.000 claims description 6
• 210000000987 immune system Anatomy 0.000 claims description 6
• 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 6
• 201000006334 interstitial nephritis Diseases 0.000 claims description 6
• 230000003903 intestinal lesions Effects 0.000 claims description 6
• 201000010659 intrinsic asthma Diseases 0.000 claims description 6
• 201000010260 leiomyoma Diseases 0.000 claims description 6
• 230000003902 lesion Effects 0.000 claims description 6
• 201000005202 lung cancer Diseases 0.000 claims description 6
• 208000020816 lung neoplasm Diseases 0.000 claims description 6
• 208000008585 mastocytosis Diseases 0.000 claims description 6
• 206010027599 migraine Diseases 0.000 claims description 6
• 208000013734 mononeuritis simplex Diseases 0.000 claims description 6
• 201000005518 mononeuropathy Diseases 0.000 claims description 6
• 230000000414 obstructive effect Effects 0.000 claims description 6
• 210000004261 periodontium Anatomy 0.000 claims description 6
• 201000006292 polyarteritis nodosa Diseases 0.000 claims description 6
• 208000005987 polymyositis Diseases 0.000 claims description 6
• 208000019629 polyneuritis Diseases 0.000 claims description 6
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 6
• 238000004321 preservation Methods 0.000 claims description 6
• 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 6
• 230000001737 promoting effect Effects 0.000 claims description 6
• 230000005855 radiation Effects 0.000 claims description 6
• 230000002441 reversible effect Effects 0.000 claims description 6
• 206010039083 rhinitis Diseases 0.000 claims description 6
• 230000035945 sensitivity Effects 0.000 claims description 6
• 230000003966 vascular damage Effects 0.000 claims description 6
• 201000005539 vernal conjunctivitis Diseases 0.000 claims description 6
• 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 5
• 206010009208 Cirrhosis alcoholic Diseases 0.000 claims description 5
• 206010063837 Reperfusion injury Diseases 0.000 claims description 5
• 206010039705 Scleritis Diseases 0.000 claims description 5
• 208000010002 alcoholic liver cirrhosis Diseases 0.000 claims description 5
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
• 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 5
• 230000006378 damage Effects 0.000 claims description 5
• 230000001506 immunosuppresive effect Effects 0.000 claims description 5
• 230000002401 inhibitory effect Effects 0.000 claims description 5
• 201000006938 muscular dystrophy Diseases 0.000 claims description 5
• 239000008194 pharmaceutical composition Substances 0.000 claims description 5
• 229960001967 tacrolimus Drugs 0.000 claims description 5
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 5
• 206010066968 Corneal leukoma Diseases 0.000 claims description 4
• 208000015181 infectious disease Diseases 0.000 claims description 4
• 208000027418 Wounds and injury Diseases 0.000 claims description 3
• 229960002706 gusperimus Drugs 0.000 claims description 3
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
• 229960002930 sirolimus Drugs 0.000 claims description 3
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 2
• PZOHOALJQOFNTB-UHFFFAOYSA-M brequinar sodium Chemical compound [Na+].N1=C2C=CC(F)=CC2=C(C([O-])=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PZOHOALJQOFNTB-UHFFFAOYSA-M 0.000 claims description 2
• 229930182912 cyclosporin Natural products 0.000 claims description 2
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims description 2
• IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims description 2
• 206010039792 Seborrhoea Diseases 0.000 claims 4
• 230000003416 augmentation Effects 0.000 claims 4
• 238000004519 manufacturing process Methods 0.000 claims 4
• 208000024908 graft versus host disease Diseases 0.000 claims 3
• 208000028867 ischemia Diseases 0.000 claims 3
• VNYSSYRCGWBHLG-AMOLWHMGSA-M leukotriene B4(1-) Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC([O-])=O VNYSSYRCGWBHLG-AMOLWHMGSA-M 0.000 claims 3
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
• 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
• 230000001476 alcoholic effect Effects 0.000 claims 2
• 101150008122 Bcan gene Proteins 0.000 claims 1
• 206010010741 Conjunctivitis Diseases 0.000 claims 1
• 208000012902 Nervous system disease Diseases 0.000 claims 1
• 208000007502 anemia Diseases 0.000 claims 1
• 229960002170 azathioprine Drugs 0.000 claims 1
• 230000001580 bacterial effect Effects 0.000 claims 1
• 230000002949 hemolytic effect Effects 0.000 claims 1
• 230000002440 hepatic effect Effects 0.000 claims 1
• 230000002458 infectious effect Effects 0.000 claims 1
• 230000003387 muscular Effects 0.000 claims 1
• 229960000951 mycophenolic acid Drugs 0.000 claims 1
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 73
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 72
• 239000000243 solution Substances 0.000 description 63
• 238000006243 chemical reaction Methods 0.000 description 59
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 36
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 36
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 29
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 25
• OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical class CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 20
• 239000000741 silica gel Substances 0.000 description 20
• 229910002027 silica gel Inorganic materials 0.000 description 20
• 239000002904 solvent Substances 0.000 description 18
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 17
• 230000002829 reductive effect Effects 0.000 description 17
• 238000004128 high performance liquid chromatography Methods 0.000 description 16
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
• 210000001744 T-lymphocyte Anatomy 0.000 description 14
• 108091006146 Channels Proteins 0.000 description 13
• 239000004480 active ingredient Substances 0.000 description 13
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 12
• 210000004027 cell Anatomy 0.000 description 12
• 238000001819 mass spectrum Methods 0.000 description 12
• 229920006395 saturated elastomer Polymers 0.000 description 12
• 150000001336 alkenes Chemical group 0.000 description 11
• QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical compound [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 11
• 230000002265 prevention Effects 0.000 description 10
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
• 150000002596 lactones Chemical class 0.000 description 9
• 238000010898 silica gel chromatography Methods 0.000 description 9
• 239000007787 solid Substances 0.000 description 9
• 239000011995 wilkinson's catalyst Substances 0.000 description 9
• KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 8
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 8
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
• 241001639960 Spachea Species 0.000 description 8
• 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 8
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
• 241000949473 Correa Species 0.000 description 7
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
• 150000001412 amines Chemical class 0.000 description 7
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
• JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 7
• 239000000047 product Substances 0.000 description 7
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 239000002775 capsule Substances 0.000 description 6
• 229910052799 carbon Inorganic materials 0.000 description 6
• WBKFWQBXFREOFH-UHFFFAOYSA-N dichloromethane;ethyl acetate Chemical compound ClCCl.CCOC(C)=O WBKFWQBXFREOFH-UHFFFAOYSA-N 0.000 description 6
• 229960003444 immunosuppressant agent Drugs 0.000 description 6
• 208000023589 ischemic disease Diseases 0.000 description 6
• 210000003734 kidney Anatomy 0.000 description 6
• 239000010410 layer Substances 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• ATYBXHSAIOKLMG-UHFFFAOYSA-N oxepin Chemical class O1C=CC=CC=C1 ATYBXHSAIOKLMG-UHFFFAOYSA-N 0.000 description 6
• 239000000843 powder Substances 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 6
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
• 241001465754 Metazoa Species 0.000 description 5
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• 239000003638 chemical reducing agent Substances 0.000 description 5
• 239000000287 crude extract Substances 0.000 description 5
• 150000002170 ethers Chemical class 0.000 description 5
• 210000001035 gastrointestinal tract Anatomy 0.000 description 5
• 238000002360 preparation method Methods 0.000 description 5
• 238000000746 purification Methods 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 239000003826 tablet Substances 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• OVJBOPBBHWOWJI-FYNXUGHNSA-N (2S)-2-[[(2S)-1-[(2S)-2-[[(aS,1R,3aS,4S,10S,16S,19R,22S,25S,28S,34S,37S,40R,45R,48S,51S,57S,60S,63S,69S,72S,75S,78S,85R,88S,91R,94S)-40-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S,3S)-2-[[(2S,3S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-methylbutanoyl]amino]hexanoyl]amino]-25,48,78,88,94-pentakis(4-aminobutyl)-a-(2-amino-2-oxoethyl)-22,63,72-tris(3-amino-3-oxopropyl)-69-benzyl-37-[(1R)-1-hydroxyethyl]-34,60-bis(hydroxymethyl)-51,57,75-trimethyl-16-(2-methylpropyl)-3a-(2-methylsulfanylethyl)-2a,3,5a,9,15,18,21,24,27,33,36,39,47,50,53,56,59,62,65,68,71,74,77,80,87,90,93,96,99-nonacosaoxo-7a,8a,42,43,82,83-hexathia-1a,2,4a,8,14,17,20,23,26,32,35,38,46,49,52,55,58,61,64,67,70,73,76,79,86,89,92,95,98-nonacosazahexacyclo[43.35.25.419,91.04,8.010,14.028,32]nonahectane-85-carbonyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](N)[C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]3CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CO)NC(=O)[C@@H](NC1=O)[C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N3)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC2=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1cnc[nH]1)C(O)=O OVJBOPBBHWOWJI-FYNXUGHNSA-N 0.000 description 4
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
• 101000997261 Centruroides margaritatus Potassium channel toxin alpha-KTx 2.2 Proteins 0.000 description 4
• 206010061218 Inflammation Diseases 0.000 description 4
• 108010002350 Interleukin-2 Proteins 0.000 description 4
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 4
• PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 4
• 238000003556 assay Methods 0.000 description 4
• 239000012298 atmosphere Substances 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
• 238000005119 centrifugation Methods 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 239000012043 crude product Substances 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• 150000002118 epoxides Chemical class 0.000 description 4
• 239000000469 ethanolic extract Substances 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 238000005194 fractionation Methods 0.000 description 4
• 210000002216 heart Anatomy 0.000 description 4
• 230000004054 inflammatory process Effects 0.000 description 4
• 238000002347 injection Methods 0.000 description 4
• 239000007924 injection Substances 0.000 description 4
• 150000002576 ketones Chemical class 0.000 description 4
• 208000017169 kidney disease Diseases 0.000 description 4
• 208000019423 liver disease Diseases 0.000 description 4
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 4
• 235000019341 magnesium sulphate Nutrition 0.000 description 4
• 239000012044 organic layer Substances 0.000 description 4
• CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 235000017557 sodium bicarbonate Nutrition 0.000 description 4
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
• KPGXUAIFQMJJFB-UHFFFAOYSA-H tungsten hexachloride Chemical compound Cl[W](Cl)(Cl)(Cl)(Cl)Cl KPGXUAIFQMJJFB-UHFFFAOYSA-H 0.000 description 4
• DAXJNUBSBFUTRP-RTQNCGMRSA-N (8r,9s,10r,13s,14s)-6-(hydroxymethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17-dione Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(CO)C2=C1 DAXJNUBSBFUTRP-RTQNCGMRSA-N 0.000 description 3
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
• BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 3
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
• 206010015218 Erythema multiforme Diseases 0.000 description 3
• 239000007995 HEPES buffer Substances 0.000 description 3
• 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 3
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
• 206010028851 Necrosis Diseases 0.000 description 3
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 3
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
• 206010052779 Transplant rejections Diseases 0.000 description 3
• 239000000443 aerosol Substances 0.000 description 3
• 230000000903 blocking effect Effects 0.000 description 3
• 239000000872 buffer Substances 0.000 description 3
• 239000011575 calcium Substances 0.000 description 3
• 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 3
• 239000003795 chemical substances by application Substances 0.000 description 3
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
• 238000004440 column chromatography Methods 0.000 description 3
• 238000002451 electron ionisation mass spectrometry Methods 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 238000010265 fast atom bombardment Methods 0.000 description 3
• 239000007903 gelatin capsule Substances 0.000 description 3
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
• 239000001257 hydrogen Substances 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 239000003112 inhibitor Substances 0.000 description 3
• 208000012947 ischemia reperfusion injury Diseases 0.000 description 3
• 208000023569 ischemic bowel disease Diseases 0.000 description 3
• 239000008101 lactose Substances 0.000 description 3
• VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 3
• 239000008297 liquid dosage form Substances 0.000 description 3
• 229910052744 lithium Inorganic materials 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 231100001016 megaloblastic anemia Toxicity 0.000 description 3
• 208000004995 necrotizing enterocolitis Diseases 0.000 description 3
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 description 3
• 108090000765 processed proteins & peptides Proteins 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 108090000623 proteins and genes Proteins 0.000 description 3
• 239000000523 sample Substances 0.000 description 3
• 230000028327 secretion Effects 0.000 description 3
• 210000003491 skin Anatomy 0.000 description 3
• 239000007921 spray Substances 0.000 description 3
• 238000003756 stirring Methods 0.000 description 3
• 229940124597 therapeutic agent Drugs 0.000 description 3
• 238000004809 thin layer chromatography Methods 0.000 description 3
• WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 3
• 229910052721 tungsten Inorganic materials 0.000 description 3
• 239000010937 tungsten Substances 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• 239000003643 water by type Substances 0.000 description 3
• IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
• UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
• 208000020084 Bone disease Diseases 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 108010023798 Charybdotoxin Proteins 0.000 description 2
• 208000027932 Collagen disease Diseases 0.000 description 2
• 208000006069 Corneal Opacity Diseases 0.000 description 2
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
• QMMFVYPAHWMCMS-UHFFFAOYSA-N Dimethyl sulfide Chemical compound CSC QMMFVYPAHWMCMS-UHFFFAOYSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• 108010010803 Gelatin Proteins 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• AXSPHUWXYSZPBG-UHFFFAOYSA-N Gusperimus hydrochloride Chemical compound Cl.Cl.Cl.NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N AXSPHUWXYSZPBG-UHFFFAOYSA-N 0.000 description 2
• 208000027761 Hepatic autoimmune disease Diseases 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
• 206010061216 Infarction Diseases 0.000 description 2
• 241001123008 Leukoma Species 0.000 description 2
• 239000002841 Lewis acid Substances 0.000 description 2
• 208000019693 Lung disease Diseases 0.000 description 2
• TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
• HZQDCMWJEBCWBR-UUOKFMHZSA-N Mizoribine Chemical compound OC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 HZQDCMWJEBCWBR-UUOKFMHZSA-N 0.000 description 2
• 206010029164 Nephrotic syndrome Diseases 0.000 description 2
• 102000005348 Neuraminidase Human genes 0.000 description 2
• 108010006232 Neuraminidase Proteins 0.000 description 2
• 208000022873 Ocular disease Diseases 0.000 description 2
• 241001494479 Pecora Species 0.000 description 2
• 102000003992 Peroxidases Human genes 0.000 description 2
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 230000006044 T cell activation Effects 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000003734 Voltage-Gated Potassium Channels Human genes 0.000 description 2
• 108090000013 Voltage-Gated Potassium Channels Proteins 0.000 description 2
• 206010000059 abdominal discomfort Diseases 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• 231100000836 acute liver failure Toxicity 0.000 description 2
• 238000003915 air pollution Methods 0.000 description 2
• 150000001298 alcohols Chemical class 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 230000007815 allergy Effects 0.000 description 2
• 235000019270 ammonium chloride Nutrition 0.000 description 2
• 150000003863 ammonium salts Chemical class 0.000 description 2
• 238000004458 analytical method Methods 0.000 description 2
• 229940121363 anti-inflammatory agent Drugs 0.000 description 2
• 239000002260 anti-inflammatory agent Substances 0.000 description 2
• 239000000010 aprotic solvent Substances 0.000 description 2
• 239000007900 aqueous suspension Substances 0.000 description 2
• 125000004429 atom Chemical group 0.000 description 2
• 230000006472 autoimmune response Effects 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 239000012267 brine Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 239000000969 carrier Substances 0.000 description 2
• 239000006285 cell suspension Substances 0.000 description 2
• 239000001913 cellulose Substances 0.000 description 2
• 235000010980 cellulose Nutrition 0.000 description 2
• 229920002678 cellulose Polymers 0.000 description 2
• OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
• 239000007891 compressed tablet Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• CNVQLPPZGABUCM-LIGYZCPXSA-N ctx toxin Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]3CSSC[C@@H](C(N[C@@H](CC=4C5=CC=CC=C5NC=4)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CCCNC(N)=N)NC3=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CO)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3NC=NC=3)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N2)C(C)C)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)O)NC1=O)=O)CCSC)C(C)C)[C@@H](C)O)NC(=O)[C@H]1NC(=O)CC1)C1=CC=CC=C1 CNVQLPPZGABUCM-LIGYZCPXSA-N 0.000 description 2
• 229960004397 cyclophosphamide Drugs 0.000 description 2
• 229940127089 cytotoxic agent Drugs 0.000 description 2
• 239000002254 cytotoxic agent Substances 0.000 description 2
• 231100000599 cytotoxic agent Toxicity 0.000 description 2
• 230000001419 dependent effect Effects 0.000 description 2
• YMWUJEATGCHHMB-DICFDUPASA-N dichloromethane-d2 Chemical compound [2H]C([2H])(Cl)Cl YMWUJEATGCHHMB-DICFDUPASA-N 0.000 description 2
• WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 2
• 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 2
• 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 125000000532 dioxanyl group Chemical group 0.000 description 2
• 125000005879 dioxolanyl group Chemical group 0.000 description 2
• 239000006185 dispersion Substances 0.000 description 2
• 210000001198 duodenum Anatomy 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• 208000030172 endocrine system disease Diseases 0.000 description 2
• 210000000918 epididymis Anatomy 0.000 description 2
• 201000010063 epididymitis Diseases 0.000 description 2
• 210000003743 erythrocyte Anatomy 0.000 description 2
• 239000003797 essential amino acid Substances 0.000 description 2
• 235000020776 essential amino acid Nutrition 0.000 description 2
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
• 230000001747 exhibiting effect Effects 0.000 description 2
• 210000001508 eye Anatomy 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 239000012894 fetal calf serum Substances 0.000 description 2
• 235000013305 food Nutrition 0.000 description 2
• 239000008273 gelatin Substances 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 235000011852 gelatine desserts Nutrition 0.000 description 2
• 150000002430 hydrocarbons Chemical group 0.000 description 2
• 238000005984 hydrogenation reaction Methods 0.000 description 2
• 230000001900 immune effect Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 239000012442 inert solvent Substances 0.000 description 2
• 230000007574 infarction Effects 0.000 description 2
• 210000004969 inflammatory cell Anatomy 0.000 description 2
• 208000028774 intestinal disease Diseases 0.000 description 2
• 230000000968 intestinal effect Effects 0.000 description 2
• 238000002955 isolation Methods 0.000 description 2
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 2
• 150000007517 lewis acids Chemical class 0.000 description 2
• 230000000670 limiting effect Effects 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• 230000002934 lysing effect Effects 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 229950000844 mizoribine Drugs 0.000 description 2
• 230000001483 mobilizing effect Effects 0.000 description 2
• 210000000214 mouth Anatomy 0.000 description 2
• 210000003205 muscle Anatomy 0.000 description 2
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 2
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
• 239000003921 oil Substances 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 238000006772 olefination reaction Methods 0.000 description 2
• 239000012074 organic phase Substances 0.000 description 2
• LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
• 210000000496 pancreas Anatomy 0.000 description 2
• 239000003182 parenteral nutrition solution Substances 0.000 description 2
• 208000028169 periodontal disease Diseases 0.000 description 2
• 108040007629 peroxidase activity proteins Proteins 0.000 description 2
• 239000012071 phase Substances 0.000 description 2
• 239000008363 phosphate buffer Substances 0.000 description 2
• 229910052700 potassium Inorganic materials 0.000 description 2
• 239000011591 potassium Substances 0.000 description 2
• 201000000742 primary sclerosing cholangitis Diseases 0.000 description 2
• 229940072288 prograf Drugs 0.000 description 2
• 238000011321 prophylaxis Methods 0.000 description 2
• QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
• 239000003223 protective agent Substances 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
• 230000009467 reduction Effects 0.000 description 2
• 230000001105 regulatory effect Effects 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 125000006413 ring segment Chemical group 0.000 description 2
• 239000000377 silicon dioxide Substances 0.000 description 2
• LFAGQMCIGQNPJG-UHFFFAOYSA-N silver cyanide Chemical compound [Ag+].N#[C-] LFAGQMCIGQNPJG-UHFFFAOYSA-N 0.000 description 2
• NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
• 229910052708 sodium Inorganic materials 0.000 description 2
• 239000011734 sodium Substances 0.000 description 2
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
• JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
• 229940054269 sodium pyruvate Drugs 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
• 238000001228 spectrum Methods 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• 239000007858 starting material Substances 0.000 description 2
• 238000001356 surgical procedure Methods 0.000 description 2
• CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
• VOITXYVAKOUIBA-UHFFFAOYSA-N triethylaluminium Chemical compound CC[Al](CC)CC VOITXYVAKOUIBA-UHFFFAOYSA-N 0.000 description 2
• ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
• 210000003905 vulva Anatomy 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• BKZOUCVNTCLNFF-IGXZVFLKSA-N (2s)-2-[(2r,3r,4s,5r,6s)-2-hydroxy-6-[(1s)-1-[(2s,5r,7s,8r,9s)-2-[(2r,5s)-5-[(2r,3s,4r,5r)-5-[(2s,3s,4s,5r,6s)-6-hydroxy-4-methoxy-3,5,6-trimethyloxan-2-yl]-4-methoxy-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-7-methoxy-2,8-dimethyl-1,10-dioxaspiro[4.5]dec Chemical compound O([C@@H]1[C@@H]2O[C@H]([C@@H](C)[C@H]2OC)[C@@]2(C)O[C@H](CC2)[C@@]2(C)O[C@]3(O[C@@H]([C@H](C)[C@@H](OC)C3)[C@@H](C)[C@@H]3[C@@H]([C@H](OC)[C@@H](C)[C@](O)([C@H](C)C(O)=O)O3)C)CC2)[C@](C)(O)[C@H](C)[C@@H](OC)[C@@H]1C BKZOUCVNTCLNFF-IGXZVFLKSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
• 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
• LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
• 239000005695 Ammonium acetate Substances 0.000 description 1
• 241000972773 Aulopiformes Species 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 206010004659 Biliary cirrhosis Diseases 0.000 description 1
• 101100446726 Caenorhabditis elegans flh-2 gene Proteins 0.000 description 1
• 241000283707 Capra Species 0.000 description 1
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• 206010012438 Dermatitis atopic Diseases 0.000 description 1
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
• 239000004593 Epoxy Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
• 102000006395 Globulins Human genes 0.000 description 1
• 108010044091 Globulins Proteins 0.000 description 1
• 208000003084 Graves Ophthalmopathy Diseases 0.000 description 1
• 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 239000007760 Iscove's Modified Dulbecco's Medium Substances 0.000 description 1
• 239000003810 Jones reagent Substances 0.000 description 1
• 108010027296 Kv1.3 Potassium Channel Proteins 0.000 description 1
• 102000018706 Kv1.3 Potassium Channel Human genes 0.000 description 1
• 229930182816 L-glutamine Natural products 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
• BKZOUCVNTCLNFF-UHFFFAOYSA-N Lonomycin Natural products COC1C(C)C(C2(C)OC(CC2)C2(C)OC3(OC(C(C)C(OC)C3)C(C)C3C(C(OC)C(C)C(O)(C(C)C(O)=O)O3)C)CC2)OC1C1OC(C)(O)C(C)C(OC)C1C BKZOUCVNTCLNFF-UHFFFAOYSA-N 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
• 229910002651 NO3 Inorganic materials 0.000 description 1
• 206010029155 Nephropathy toxic Diseases 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
• LPMXVESGRSUGHW-GHYGWZAOSA-N Ouabain Natural products O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1)[C@H]1C[C@@H](O)[C@@]2(CO)[C@@](O)(C1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)C[C@@H](O)[C@H]21 LPMXVESGRSUGHW-GHYGWZAOSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 239000004698 Polyethylene Substances 0.000 description 1
• 102000004257 Potassium Channel Human genes 0.000 description 1
• 208000001647 Renal Insufficiency Diseases 0.000 description 1
• DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 108010090804 Streptavidin Proteins 0.000 description 1
• 244000166550 Strophanthus gratus Species 0.000 description 1
• QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
• 230000006052 T cell proliferation Effects 0.000 description 1
• 241001128518 Tabris Species 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 229910003091 WCl6 Inorganic materials 0.000 description 1
• JEDZLBFUGJTJGQ-UHFFFAOYSA-N [Na].COCCO[AlH]OCCOC Chemical compound [Na].COCCO[AlH]OCCOC JEDZLBFUGJTJGQ-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 239000002253 acid Substances 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000036982 action potential Effects 0.000 description 1
• 125000003545 alkoxy group Chemical group 0.000 description 1
• 125000005910 alkyl carbonate group Chemical group 0.000 description 1
• 150000001350 alkyl halides Chemical class 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 229910052782 aluminium Inorganic materials 0.000 description 1
• XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
• 150000001413 amino acids Chemical class 0.000 description 1
• 235000019257 ammonium acetate Nutrition 0.000 description 1
• 229940043376 ammonium acetate Drugs 0.000 description 1
• 230000003064 anti-oxidating effect Effects 0.000 description 1
• 238000009175 antibody therapy Methods 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 235000010323 ascorbic acid Nutrition 0.000 description 1
• 239000011668 ascorbic acid Substances 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 201000008937 atopic dermatitis Diseases 0.000 description 1
• 229960004360 azathioprine sodium Drugs 0.000 description 1
• 229960000686 benzalkonium chloride Drugs 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
• PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
• CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 230000000975 bioactive effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 230000015572 biosynthetic process Effects 0.000 description 1
• AZWXAPCAJCYGIA-UHFFFAOYSA-N bis(2-methylpropyl)alumane Chemical compound CC(C)C[AlH]CC(C)C AZWXAPCAJCYGIA-UHFFFAOYSA-N 0.000 description 1
• 210000000601 blood cell Anatomy 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 125000001246 bromo group Chemical group Br* 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 230000004094 calcium homeostasis Effects 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 150000001721 carbon Chemical group 0.000 description 1
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
• 150000001735 carboxylic acids Chemical class 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 229940107810 cellcept Drugs 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 150000001793 charged compounds Chemical class 0.000 description 1
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
• 150000001805 chlorine compounds Chemical class 0.000 description 1
• 125000001309 chloro group Chemical group Cl* 0.000 description 1
• 229960004926 chlorobutanol Drugs 0.000 description 1
• KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
• 238000004040 coloring Methods 0.000 description 1
• 229940000425 combination drug Drugs 0.000 description 1
• 238000002648 combination therapy Methods 0.000 description 1
• 229940125904 compound 1 Drugs 0.000 description 1
• 210000004087 cornea Anatomy 0.000 description 1
• 239000003246 corticosteroid Substances 0.000 description 1
• 229960001334 corticosteroids Drugs 0.000 description 1
• 235000012343 cottonseed oil Nutrition 0.000 description 1
• 239000002385 cottonseed oil Substances 0.000 description 1
• 238000002425 crystallisation Methods 0.000 description 1
• 230000008025 crystallization Effects 0.000 description 1
• 238000012258 culturing Methods 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 125000000753 cycloalkyl group Chemical group 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• 239000001177 diphosphate Substances 0.000 description 1
• XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
• 235000011180 diphosphates Nutrition 0.000 description 1
• 238000006073 displacement reaction Methods 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 239000006196 drop Substances 0.000 description 1
• 238000000132 electrospray ionisation Methods 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 238000011049 filling Methods 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 239000003365 glass fiber Substances 0.000 description 1
• 239000008103 glucose Substances 0.000 description 1
• 150000002334 glycols Chemical class 0.000 description 1
• 239000008187 granular material Substances 0.000 description 1
• 150000004795 grignard reagents Chemical class 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229910052736 halogen Inorganic materials 0.000 description 1
• 150000002367 halogens Chemical class 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 238000010438 heat treatment Methods 0.000 description 1
• 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 230000003284 homeostatic effect Effects 0.000 description 1
• 230000009097 homeostatic mechanism Effects 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• 229930195733 hydrocarbon Natural products 0.000 description 1
• 230000004957 immunoregulator effect Effects 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000004073 interleukin-2 production Effects 0.000 description 1
• 230000003834 intracellular effect Effects 0.000 description 1
• 238000007918 intramuscular administration Methods 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 125000002346 iodo group Chemical group I* 0.000 description 1
• 230000019948 ion homeostasis Effects 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 201000006370 kidney failure Diseases 0.000 description 1
• 229960000681 leflunomide Drugs 0.000 description 1
• 239000007788 liquid Substances 0.000 description 1
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
• 238000005567 liquid scintillation counting Methods 0.000 description 1
• 230000003908 liver function Effects 0.000 description 1
• 229910001629 magnesium chloride Inorganic materials 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000028161 membrane depolarization Effects 0.000 description 1
• VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
• GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 1
• 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 229960002216 methylparaben Drugs 0.000 description 1
• 229940016286 microcrystalline cellulose Drugs 0.000 description 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
• 239000008108 microcrystalline cellulose Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004118 muscle contraction Effects 0.000 description 1
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 1
• 229960004866 mycophenolate mofetil Drugs 0.000 description 1
• 230000003589 nefrotoxic effect Effects 0.000 description 1
• 229940063121 neoral Drugs 0.000 description 1
• 231100000381 nephrotoxic Toxicity 0.000 description 1
• 231100000417 nephrotoxicity Toxicity 0.000 description 1
• 230000007694 nephrotoxicity Effects 0.000 description 1
• 230000000955 neuroendocrine Effects 0.000 description 1
• 210000002569 neuron Anatomy 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 125000004433 nitrogen atom Chemical group N* 0.000 description 1
• 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
• 239000012038 nucleophile Substances 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000004006 olive oil Substances 0.000 description 1
• 235000008390 olive oil Nutrition 0.000 description 1
• 229940054534 ophthalmic solution Drugs 0.000 description 1
• 239000002997 ophthalmic solution Substances 0.000 description 1
• 229940100654 ophthalmic suspension Drugs 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 239000012285 osmium tetroxide Substances 0.000 description 1
• 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
• 210000002997 osteoclast Anatomy 0.000 description 1
• LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
• 229960003343 ouabain Drugs 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 238000007248 oxidative elimination reaction Methods 0.000 description 1
• 238000006385 ozonation reaction Methods 0.000 description 1
• 238000005949 ozonolysis reaction Methods 0.000 description 1
• 235000019629 palatability Nutrition 0.000 description 1
• 238000007911 parenteral administration Methods 0.000 description 1
• 230000008506 pathogenesis Effects 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 229920000573 polyethylene Polymers 0.000 description 1
• 108020001213 potassium channel Proteins 0.000 description 1
• 230000003389 potentiating effect Effects 0.000 description 1
• 238000011533 pre-incubation Methods 0.000 description 1
• OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
• 229960005205 prednisolone Drugs 0.000 description 1
• 238000012746 preparative thin layer chromatography Methods 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
• 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
• 229960003415 propylparaben Drugs 0.000 description 1
• 125000003373 pyrazinyl group Chemical group 0.000 description 1
• 125000002098 pyridazinyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000036390 resting membrane potential Effects 0.000 description 1
• 229910052701 rubidium Inorganic materials 0.000 description 1
• 229910001927 ruthenium tetroxide Inorganic materials 0.000 description 1
• YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
• 229960001860 salicylate Drugs 0.000 description 1
• 235000019515 salmon Nutrition 0.000 description 1
• 229940063122 sandimmune Drugs 0.000 description 1
• 238000009738 saturating Methods 0.000 description 1
• 239000002795 scorpion venom Substances 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000003335 secondary amines Chemical class 0.000 description 1
• 229940098221 silver cyanide Drugs 0.000 description 1
• 229910001923 silver oxide Inorganic materials 0.000 description 1
• WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
• 235000010234 sodium benzoate Nutrition 0.000 description 1
• 239000004299 sodium benzoate Substances 0.000 description 1
• 239000012419 sodium bis(2-methoxyethoxy)aluminum hydride Substances 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• 239000011780 sodium chloride Substances 0.000 description 1
• 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• WISNYKIQFMKSDQ-UHFFFAOYSA-N sodium;6-(3-methyl-5-nitroimidazol-4-yl)sulfanylpurin-9-ide Chemical compound [Na+].CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1[N-]C=N2 WISNYKIQFMKSDQ-UHFFFAOYSA-N 0.000 description 1
• 239000007909 solid dosage form Substances 0.000 description 1
• 239000012453 solvate Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 238000010561 standard procedure Methods 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 238000007920 subcutaneous administration Methods 0.000 description 1
• 239000000758 substrate Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 150000003871 sulfonates Chemical class 0.000 description 1
• YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000000829 suppository Substances 0.000 description 1
• 238000013268 sustained release Methods 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000006188 syrup Substances 0.000 description 1
• 235000020357 syrup Nutrition 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• HYWCXWRMUZYRPH-UHFFFAOYSA-N trimethyl(prop-2-enyl)silane Chemical compound C[Si](C)(C)CC=C HYWCXWRMUZYRPH-UHFFFAOYSA-N 0.000 description 1
• 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• WMSKLFZMWPHWJI-UHFFFAOYSA-N tris(phenoxymethyl)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1OC[PH+](COC=1C=CC=CC=1)COC1=CC=CC=C1 WMSKLFZMWPHWJI-UHFFFAOYSA-N 0.000 description 1
• 238000002211 ultraviolet spectrum Methods 0.000 description 1
• MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
• FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
• 235000012141 vanillin Nutrition 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 239000008215 water for injection Substances 0.000 description 1
• 238000010626 work up procedure Methods 0.000 description 1